Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Compass (NYSE:COMP) and its peers.
Q4 Rundown: RTX (NYSE:RTX) Vs Other Defense Contractors Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how RTX (NYSE:RTX) and the rest of the defense contractors stocks fared in Q4.
Spotting Winners: NN (NASDAQ:NNBR) And Engineered Components and Systems Stocks In Q4
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at NN (NASDAQ:NNBR) and the best and worst performers in the engineered components and systems industry.
3 Reasons to Sell PBI and 1 Stock to Buy Instead
While the broader market has struggled with the S&P 500 down 1.3% since September 2024, Pitney Bowes has surged ahead as its stock price has climbed by 39.6% to $9.27 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Winners And Losers Of Q4: Bel Fuse (NASDAQ:BELFA) Vs The Rest Of The Electronic Components Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Bel Fuse (NASDAQ:BELFA) and the rest of the electronic components stocks fared in Q4.
3 Reasons IART is Risky and 1 Stock to Buy Instead
While the broader market has struggled with the S&P 500 down 1.3% since September 2024, Integra LifeSciences has surged ahead as its stock price has climbed by 31.6% to $22.79 per share. This performance may have investors wondering how to approach the situation.
3 Reasons to Avoid TASK and 1 Stock to Buy Instead
TaskUs currently trades at $13.28 per share and has shown little upside over the past six months, posting a middling return of 3.6%.
3 Reasons to Sell ELAN and 1 Stock to Buy Instead
Elanco has gotten torched over the last six months - since September 2024, its stock price has dropped 28.5% to $10.39 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Q4 Rundown: Hain Celestial (NASDAQ:HAIN) Vs Other Shelf-Stable Food Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the shelf-stable food industry, including Hain Celestial (NASDAQ:HAIN) and its peers.
3 Reasons SEM is Risky and 1 Stock to Buy Instead
The past six months haven’t been great for Select Medical. It just made a new 52-week low of $15.71, and shareholders have lost 55.5% of their capital. This was partly due to its softer quarterly results and might have investors contemplating their next move.